Welcome to the first edition of the JACC: Heart Failure Editor’s Update. I am excited to have this opportunity to share my thoughts about papers and activities of the journal. I hope to highlight some of the outstanding contributions to the journal, and stimulate thoughtful discussion about some of the controversies and opportunities we face as journal editors. I want to hear from the readership on some of these issues, and what ideas you may have. This is intended to be a forum for communication and feedback. I will also highlight a few articles from each month’s issue. The April issue is a mini focus on Hospitalized Heart Failure and Congestion. In future editions, I will highlight the hardworking Deputy Editors, Associate Editors and Editorial Board of JACC: Heart Failure. If there are specific topics you want to hear about, please let us know! I look forward to hearing from you.
Heart failure research was well represented at ACC.18. The Eugene Braunwald Keynote Lecture on “The Relationship Between Heart Failure and Type 2 Diabetes” by Dr. John J.V. McMurray, Professor of Cardiology at the University of Glasgow, was excellent and insightful. The session began with each Editor-in-Chief of the JACC journals briefly presenting what we identified as our top papers from 2017, which included my presentation on The Best of JACC Heart Failure: Practice Changing Research. Below is a list of papers our Associate Editor team selected as most impactful among the many outstanding papers published in 2017.
MuthiahVaduganathan, Brian L.Claggett, et al
Sudden death was shown to account for approximately 20% of deaths in HFpEF, with male gender and insulin-treated diabetes predicting higher risk for sudden death or aborted cardiac arrest. The data from this study may guide future efforts to prevent sudden death in HFpEF.
MuthiahVaduganathan, BrianClaggett, et al
This research showed that therapy-related changes in natriuretic peptides (NPs) appeared to be modestly correlated with longer-term therapeutic effects on hospitalization for heart failure, but not with effects on all-cause mortality, suggesting caution regarding the use of NPs in phase II trials for decision-making regarding phase III trials.
An Editorial Comment which suggests that additional studies are necessary before cardiac biomarkers can be used as acceptable endpoints.
I have to ask Jim Januzzi, Mike Felker and their biomarker colleagues - why hasn’t the heart failure field advanced further with biomarkers as surrogate endpoints (like LDL) and have we advanced at all with results such as the GUIDE-IT study? Let’s hear from you on this topic.
I look forward to highlighting more of our excellent publications and highlighted topics in next month’s issue.